The company ‘Regeneron Pharmaceuticals Inc., announced, the Medicines and Healthcare Products Regulatory Agency (MHRA) of United Kingdom has given the approval to the Conditional Marketing Authorization (CMA) for the imdevimab and casirivimab antibody cocktail, that has been known as REGEN-COV in the United States and Ronapreve in the United Kingdom and several other countries for the purpose of prevention and treatment of the acute corona virus infection.
In addition to Conditional Marketing Authorization (CMA), that is affecting the people of Scotland, United Kingdom and Wales, and the MHRA of United Kingdom has also been authorized for the emergency supply of the antibody cocktail for the purpose of prevention and treatment of the acute novel corona virus infection for the people living in the country of Northern Ireland.
George D. Yancopoulos, chief scientific officer and president of Regeneron said, in spite of the remarkable collective efforts of the healthcare professionals, governments and the communities across the world, the novel corona virus has been continuing to cause some significant death and illness along with the new and highly mutated novel corona virus variants responsible in making the fight more challenging.
He also said, in addition to the prevention of the death and hospitalization in the patients, which are already infected with the corona virus, and they are now also encouraged that, the governments for the purpose of recognizing the health benefits of REGEN-COV in the prevention of the infection, also including the immunocompromised people, who might not respond to the vaccines because of an underlying medical condition and also because of the medicines that are used for the treatment of an underlying condition.
